Additionally, the clinical utility of biomarkers such as CPS and TPS remains uncertain, which may introduce bias when comparing PD-L1 expression outcomes across different PD-1 inhibitor trials in the second-line treatment of locally advanced ESCC. Here, PDCD1 is linked to esophageal squamous cell carcinoma.